Sponsored by: Investment Center

Something new in your business?  Click here to submit your business press release

Chamber Corner | Main Street News | Job Hunt | Classifieds | Calendar | Illinois Lottery 

Wall Street dips as investors wary before jobs data

Send a link to a friend  Share

[April 04, 2014]  By Caroline Valetkevitch

NEW YORK (Reuters) — U.S. stocks slipped on Thursday, as investors turned cautious ahead of Friday's monthly jobs report, while a drop in biotech and momentum shares dragged the Nasdaq down nearly 1 percent.

The Dow ended down just a fraction of a point, within about 4 points of its record closing high of 16,576.66 set on December 31. The Dow posted an all-time intraday high during the session.

Market outperformers in the Internet and biotech sectors lost ground, resuming a selloff from March after some recent gains. Two weeks ago, biotechs suffered their worst day since 2011.

"That's a buying opportunity in our view. We think (biotech) will come roaring back. It's not just going to have one good year and be done," said Randy Warren, chief investment officer of Warren Financial Service in Exton, Pennsylvania.

The Nasdaq biotechnology index <.NBI> slid 2.7 percent.

Among momentum stocks, the shares of Tesla Motors <TSLA.O>, the electric car maker, fell 2.1 percent to $225.40 and the shares of Netflix Inc <NFLX.O>, the online movie rental company, lost 2.3 percent to close at $354.69. Facebook <FB.O> shares fell 5.2 percent to end at $59.49.


Investors were reluctant to make big bets ahead of Friday's nonfarm payrolls report, when they will be looking for evidence that recent weather-related weakness in the economy has passed. Economists expect that employers added 200,000 jobs to nonfarm payrolls in March, according to a Reuters poll.

The Dow Jones industrial average <.DJI> dipped 0.45 of a point to close at 16,572.55, after hitting an intraday record of 16,604.15.

The S&P 500 <.SPX> slipped 2.13 points or 0.11 percent, to finish at 1,888.77. It also hit an intraday record high of 1,893.80. The Nasdaq Composite <.IXIC> dropped 38.716 points or 0.91 percent, to end at 4,237.74.

The Global X Social Media ETF <SOCL.O>, which includes Facebook, LinkedIn Corp <LNKD.N> and Groupon Inc <GRPN.O>, fell 3.4 percent.

Some analysts said the selloff in "momentum" stocks has yet to run its course

The options market also focused on momentum stocks, with Tesla Motors remaining a favorite with the speculative crowd for a second day. The total option volume by afternoon was running at about a 30 percent mark-up to what's typically seen.

Anadarko Petroleum Corp <APC.N> shares jumped 14.5 percent to close at $99.02 following news that the company will pay $5.15 billion to settle years of litigation over pollution clean-up claims related to uranium deposits, wood creosote and rocket fuel processing. The agreement marked the biggest environmental bankruptcy settlement on record.

[to top of second column]

Shares of Barnes & Noble Inc <BKS.N> plunged 13.5 percent to $19.12 after Liberty Media Corp <LMCA.O> said it has sold almost all of its stake in the company, ending a nearly three-year bet that the struggling retailer would emerge as a dominant seller of e-books.

The S&P 500 now consists of 501 stocks, with the index including both Google Inc's Class A <GOOGL.O> and Class C <GOOG.O> shares after the company's special dividend. Google's Class A shares rose 0.6 percent to $571.50 while its Class C shares gained 0.5 percent to $569.74.

On the economic front, the U.S. trade deficit unexpectedly widened in February to $42.3 billion as exports hit a five-month low, suggesting that first-quarter growth could be much weaker than initially expected.

A bright spot came from the services sector, where growth accelerated in March after being hampered by unusually cold weather, according to the Institute for Supply Management's services-sector index.

In the biopharmaceutical sector, Gilead Sciences Inc <GILD.O> said late Wednesday that a trial of its hepatitis C drug sofosbuvir, sold under the brand name Sovaldi in the United States, showed the drug was safe and effective in treating Japanese patients infected with a common form of the virus. Its stock edged up 0.1 percent to close at $74.

About 6.0 billion shares changed hands on U.S. exchanges, below the 6.4 billion average so far this month, according to data from BATS Global Markets.


Decliners beat advancers on the New York Stock Exchange by 1,772 to 1,220 and on the Nasdaq by 1,837 to 775.

(Additional reporting by Angela Moon; editing by Nick Zieminski and Jan Paschal)

[© 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

< Recent articles

Back to top